Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Zenagamtide versus semaglutide for blood sugar and weight in type 2 diabetes

Compares zenagamtide with semaglutide in adults with type 2 diabetes taking metformin or SGLT2i.

Key facts

Who runs it
Novo Nordisk A/S
Where
Beijing, Changde, Changzhou, Chongqing, Hengshui, Jinan, Kaifeng, Langfang, Luoyang, Nanjing, Shantou, Shijiazhuang, Suzhou, Xining, Zhengzhou, and Zhenjiang, ChinaSee the 18 sitesAlso in 15 other countries, 134 sites
Trial code
Registry title
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
Status
Not yet recruiting
Phase
Phase 3
People taking part
1,060 people, planned
Started
10 Nov 2026
Expected to end
28 Aug 2028
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Zenagamtide
  • Semaglutide
  • Placebo zenagamtide
  • Placebo semaglutide
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Male or female (sex assigned at birth, inclusive of all gender identities)
  • Age 18 years or above at the time of signing the informed consent
  • Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥ )180 days before screening
  • On stable daily dose(s) of metformin, SGLT2 (sodium-glucose cotransporter 2) inhibitor, or both (at effective or maximum tolerated dose as judged by the investigator) prior to screening

Who cannot take part

  • Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes is allowed as well as short term insulin treatment for a maximum of 14 consecutive days. However, insulin treatment for gestational diabetes or short-term insulin treatment for a maximum of 14 consecutive days is allowed
  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening
  • Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation
  • Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method
  • Planned coronary, carotid or peripheral artery revascularisation

Where in China

Also in 15 other countries, 134 sites

  • Peking University People's Hospital-EndocrinologyBeijing, ChinaContact: Novo NordiskNo longer taking part
  • The First People's Hospital of Changde City-EndocrinologyChangde, ChinaContact: Novo NordiskNo longer taking part
  • Changzhou No.2 People's Hospital-EndocrinologyChangzhou, ChinaContact: Novo NordiskNo longer taking part
  • Chongqing University Three Gorges Hospital-EndocrinologyChongqing, ChinaContact: Novo NordiskNo longer taking part
  • The Second Affiliated Hospital of Chongqing Medical University-EndocrinologyChongqing, ChinaContact: Novo NordiskNo longer taking part
  • Hengshui People's Hospital (Harrison International Peace Hospital)-EndocrinologyHengshui, ChinaContact: Novo NordiskNo longer taking part
  • Jinan Central Hospital-General MedicineJinan, ChinaContact: Novo NordiskNo longer taking part
  • Huaihe Hospital of Henan University-EndocrinologyKaifeng, ChinaContact: Novo NordiskNo longer taking part
  • Hebei PetroChina Central Hospital-EndocrinologyLangfang, ChinaContact: Novo NordiskNo longer taking part
  • The First Affiliated Hospital of Henan University of Science and Technology-EndocrinologyLuoyang, ChinaContact: Novo NordiskNo longer taking part
  • Nanjing First Hospital-EndocriniologyNanjing, ChinaContact: Novo NordiskNo longer taking part
  • The Second Affiliated Hospital of Nanjing Medical University-EndocrinologyNanjing, ChinaContact: Novo NordiskNo longer taking part
  • The Second Affiliated Hospital of Shantou University Medical College-EndocrinologyShantou, ChinaContact: Novo NordiskNo longer taking part
  • The First Hospital of Hebei Medical University-EndocrinologyShijiazhuang, ChinaContact: Novo NordiskNo longer taking part
  • The Second Affiliated Hospital of Soochow University-EndocrinologySuzhou, ChinaContact: Novo NordiskNo longer taking part
  • Qinghai Provincial People's Hospital-EndocrinologyXining, ChinaContact: Novo NordiskNo longer taking part
  • The Second Affiliated Hospital of Zhengzhou University-EndocrinologyZhengzhou, ChinaContact: Novo NordiskNo longer taking part
  • The Affiliated Hospital of Jiangsu University-EndocrinologyZhenjiang, ChinaContact: Novo NordiskNo longer taking part

About the trial

What the trial wants to find out

The study is testing zenagamtide in participants with type 2 diabetes. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. Participants will either get zenagamtide or semaglutide. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.

The 4 groups in the trial

  • ZenagamtideTreatment being tested

    Participants will receive zenagamtide subcutaneously.

  • SemaglutideExisting treatment, for comparison

    Participants will receive semaglutide subcutaneously.

  • Placebo zenagamtidePlacebo, for comparison

    Participants will receive placebo matched to zenagamtide subcutaneously.

  • Placebo semaglutidePlacebo, for comparison

    Participants will receive placebo matched to semaglutide subcutaneously.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Lower Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both
Plain-language title
Zenagamtide versus semaglutide for blood sugar and weight in type 2 diabetesGenerated from the registry record. The registry title is the official one.
Record updated
12 November 2026